Hookipa Pharma Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview

Hookipa Pharma

11/03/2024 13:05

* HOOKIPA Pharma Inc  HOOK.OQ   HOOK.O  is expected to show
a fall
in quarterly revenue when it reports  results on March 13
(estimated) for the period ending December 31 2023
    * The New York City-based  company is expected to report a
41.8% decrease in revenue to $4.555 million from $7.83 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for HOOKIPA Pharma Inc is
for a
loss of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for HOOKIPA
Pharma
Inc is $4.50​, above​ its last closing price of $0.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.23       -0.21      -0.17     Beat    19
 Jun. 30 2023  -0.19       -0.21      -0.22     Missed  -5.3
 Mar. 31 2023  -0.22       -0.23      -0.27     Missed  -19.5​
 Dec. 31 2022  -0.18       -0.21      -0.17     Beat    20.9
 ​​Sep.        -0.29       -0.28      -0.25     Beat    11.2
 30 2022                                                
 Jun. 30 2022  -0.36       -0.36      -0.23     Beat    36.1​
 Mar. 31 2022  -0.24       -0.24      -0.40     Missed  -66.7
 Dec. 31 2021  -0.63       -0.58      -0.65     Missed  -12.3
 This summary was machine generated March 11 at 13:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)